Evolus, Inc.
- EOLS
- NASDAQ
- Drug Manufacturers - Specialty & Generic
- Medical Aesthetics Injectables
- Neuromodulators
$7.36
Today +3.66%Quote Oct 19, 2026, 08:00 PM UTC
−6.36%over the last month
Max drawdown −13.9%From 1-month high −10.8%3 months +26.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Evolus
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation.
Where the money comes from
Q2 2026 revenue $84.1M
- Product$83.3M99.1%
- Service$734,0000.9%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Employees
353
Founded
2012
Market value
$486.1M
Quote Oct 19
Floor
$7.32
0.6% below price
Resistance
$7.61
3.4% above price
Price vs analyst targets
13 analysts
Lowest target
$13.00Highest target
$27.00
$13.00Highest target
$27.00
- Price $7.36
- Average target $18.40
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 150% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about EOLSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free